Abbvie Inc
SWB:4AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abbvie Inc
SWB:4AB
|
US |
|
L
|
Li Ning Co Ltd
XMUN:LNLB
|
CN |
|
B
|
Berry Global Group Inc
F:BP0
|
US |
|
G
|
General Electric Co
SGO:GE
|
US |
|
C
|
China Literature Ltd
SWB:C2X
|
CN |
|
Anheuser-Busch Inbev SA
OTC:BUDFF
|
BE |
|
L
|
Lockheed Martin Corp
XBER:LOM
|
US |
|
N
|
NSL Foods PCL
SET:NSL
|
TH |
|
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
|
US |
|
R
|
Rio Tinto PLC
F:RIO1
|
UK |
Wall St Price Targets
4AB Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for 4AB is 215.08 EUR with a low forecast of 159.1 EUR and a high forecast of 288.76 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 4AB's stock price target?
Price Target
215.08
EUR
According to Wall Street analysts, the average 1-year price target for 4AB is 215.08 EUR with a low forecast of 159.1 EUR and a high forecast of 288.76 EUR.
What is the Revenue forecast for Abbvie Inc?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 5%.
What is the Operating Income forecast for Abbvie Inc?
Projected CAGR
11%
Over the last 14 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 8 years is 11%.
What is the Net Income forecast for Abbvie Inc?
Projected CAGR
32%
Over the last 14 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 8 years is 32%.
